HALO — HALOZYME THERAPEUTICS, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1159036 ·
Last close
$95.97
Market Cap
$10.94B
52W High
$134.00
52W Low
$61.23
ADV30
2,321,087
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 492,974,000 410,499,000 294,969,000 247,049,000 3,473,346,000 1,029,988,000 3,528,585,000
Jun 2026 480,999,000 401,828,000 287,654,000 229,913,000 2,577,408,000 163,138,000 2,433,865,000
Mar 2026 376,708,000 297,470,000 184,517,000 150,049,000 2,672,719,000 309,749,000 2,453,083,000
Dec 2025 451,767,000 372,997,000 240,696,000 -141,591,000 2,525,323,000 133,820,000 2,476,509,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$818,595,000
Investing CF
$-605,719,000
Financing CF
$-110,751,000
CapEx
$-300,142,000
Dividends Paid
—
Buybacks
$-38,883,000
EPS Diluted TTM
$3.35
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$151,259,000
Inventory
$137,135,000
Receivables
$455,827,000
ST Investments
$67,865,000
EBIT TTM
$603,641,000
Pretax Income TTM
$583,338,000
Interest Exp TTM
$20,303,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,802,448,000
EBITDA
$1,143,614,976
Free Cash Flow
$411,703,488
Enterprise Value
$13,990,772,736
Total Cash
$1,074,386,944
Total Debt
$3,250,302,976
Shares Out
114,010,000
Trailing EPS
$4.00
Book Value
$-0.48
ROE
216.4%
ROA
22.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,396,611,000 802,593,000 316,889,000 2,525,323,000 2,476,509,000 48,814,000 651,558,000
Dec 2024 1,015,324,000 551,475,000 444,091,000 2,063,477,000 1,699,656,000 363,821,000 479,064,000
Dec 2023 829,253,000 337,574,000 281,594,000 1,733,270,000 1,649,462,000 83,808,000 388,571,000
Dec 2022 660,116,000 267,531,000 202,129,000 1,841,511,000 1,671,713,000 169,798,000 240,110,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$1,663,738,000
NetIncome TTM
$413,596,000
OpCashFlow TTM
—
Assets (Latest)
$2,577,408,000
Forward EPS
$10.54

Max Pain — expiry 2026-12-18

max pain strike: $90.00 · spot: $95.80 · call oi: 4,599 · put oi: 3,145
Expected Move to 2026-12-18: ±$8.30 (8.66%) — implied range $87.50 – $104.10 · ATM straddle on $95.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TECH BIO-TECHNE Corp $11.41B $72.63 —
KYMR Kymera Therapeutics, Inc. $10.37B $121.52 —
RGEN REPLIGEN CORP $10.30B $162.18 —
QGEN QIAGEN N.V. $10.27B $49.75 —
PCVX Vaxcyte, Inc. $9.40B $59.40 —

News headlines (Yahoo Finance, 1h cache)

Halozyme Therapeutics (HALO) Stock Gets Fair Value Boost After Q3 Analyst Revisions
2026-11-12 12:13 · Yahoo
Halozyme Therapeutics (HALO) Stock Looks In Line As ENHANZE Approval Lands
2026-11-12 11:12 · Yahoo
Can You Make Money Off Halozyme Stock Now?
2026-11-11 20:55 · Yahoo
Halozyme Therapeutics' Current Royalty Portfolio Expected to Peak in 2029, Morgan Stanley Says
2026-11-11 16:11 · Yahoo
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
2026-11-10 19:42 · Yahoo
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
2026-11-10 13:40 · Yahoo
HALO Q3 2026 deep dive: royalty expansion and next-gen platform investments drive outlook update
2026-11-10 11:49 · Yahoo
Halozyme Therapeutics (HALO) Following Record Results And Higher Guidance Is The Stock Still Undervalued
2026-11-06 17:15 · Yahoo
Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher Guidance
2026-11-06 16:58 · Yahoo
Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
2026-11-06 15:04 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.